Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Nov 25:12:263-266.
doi: 10.2147/RRTM.S341711. eCollection 2021.

The First Experience of Effective 3rd Line Antiretroviral Therapy - A Case of 40-Year-Old Female Retroviral-Infected Patient at Hawassa University Comprehensive Specialized Hospital, Hawassa, Sidama, Ethiopia

Worku Ketema  1 , Kefyalew Taye  1 , Mulugeta Sitot Shibeshi  1 , Negash Tagesse  1 , Agete Tadewos Hirigo  2 , Kindie Woubishet  3 , Selamawit Gutema  3 , Aberash Eifa  4 , Alemayehu Toma  5
Affiliations
Case Reports

The First Experience of Effective 3rd Line Antiretroviral Therapy - A Case of 40-Year-Old Female Retroviral-Infected Patient at Hawassa University Comprehensive Specialized Hospital, Hawassa, Sidama, Ethiopia

Worku Ketema et al. Res Rep Trop Med. .

Abstract

Background: Treatment failure continues to be an impediment to the efficacy of highly active antiretroviral therapy (HART) in the treatment of human immunodeficiency virus type 1 infection (HIV-1). The World Health Organization (WHO) recommends third-line antiretroviral therapy (ART) for patients who have failed second-line ART. Darunavir (DRV) boosted with ritonavir (DRV/r) has a higher genetic barrier to resistance, is active against multidrug-resistant HIV isolates, retaining virological activity even when multiple protease mutations are present, and has been shown to be cost-effective when compared to other boosted protease inhibitors (PIs).

Case summary: This is a case of a 40-year-old female known HIV/AIDS patient who has been on ART for the last 14 years with good adherence and regular follow-up, and who is now on 3rd line ART medication with TLD (tenofovir/lamivudine/dolutegravir)+DRV/r (in her 11th month) after being diagnosed with second-line treatment failure. After 6 months and 1 week of therapy, the viral load (VL) was sent, and the result was undetectable. The patient's clinical conditions had greatly improved.

Conclusion: Third-line ART therapy, which was once thought to be a salvageable treatment, is now the primary option for second-line ART failure. TLD in combination with ritonavir-boosted darunavir is found to be effective at lowering viral loads in the blood below detectable limits. Despite a lack of data on the use of third-line ART in Ethiopia, access to third-line ART containing ritonavir-boosted darunavir is recommended because it has been shown to be an effective alternative for patients who have failed second-line ART. We recommend that more research be done with a larger sample size, and that the findings in this paper be used with caution.

Keywords: darunavir; third line ART; undetectable viral load.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest for this work.

Similar articles

See all similar articles

References

    1. Liu Z, Tran TT, Pham L, et al. Darunavir-resistant HIV-1 protease constructs uphold a conformational selection hypothesis for drug resistance. MDP J Virus. 2020;12(11):1275. doi:10.3390/v12111275 - DOI - PMC - PubMed
    1. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700. doi:10.1016/S0140-6736(13)61221-0 - DOI - PubMed
    1. Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the Phase III VIKING-3 study. J Infect Dis. 2014;210(3):354. doi:10.1093/infdis/jiu051 - DOI - PMC - PubMed
    1. World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens; 2018:3–6. Available from: https://apps.who.int/iris/handle/10665/277395. Accessed August, 2021.
    1. FMoHo E. National consolidated guidelines for comprehensive HIV prevention, care and treatment; 2018.

Publication types

LinkOut - more resources